Edition:
United Kingdom

Nippon Shinyaku to start phase 2 clinical study of NS-065


Wednesday, 30 Mar 2016 

Nippon Shinyaku Co Ltd:Submitted to the Food and Drug Administration (FDA) on March 25, 2016, an Investigational New Drug (IND) Application for a phase 2 clinical study of NS-065, the first antisense oligonucleotide discovered in Japan for the treatment of Duchenne Muscular Dystrophy (DMD). 

Latest Developments forNippon Shinyaku Co Ltd

Company Quote

8200.0
-20.0 -0.24%
15 Dec 2017